Market closedNon-fractional
Reneo Pharmaceuticals/RPHM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Ticker
RPHM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Irvine, United States
Employees
8
Website
reneopharma.com
RPHM Metrics
BasicAdvanced
$50M
Market cap
-
P/E ratio
-$2.16
EPS
0.23
Beta
-
Dividend rate
Price and volume
Market cap
$50M
Beta
0.23
Financial strength
Current ratio
29.825
Quick ratio
29.437
Long term debt to equity
0.709
Total debt to equity
1.116
Management effectiveness
Return on assets (TTM)
-51.66%
Return on equity (TTM)
-84.01%
Valuation
Price to book
0.62
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-0.645
Growth
Earnings per share change (TTM)
-1.60%
3-year earnings per share growth (CAGR)
-41.71%
What the Analysts think about RPHM
Analyst Ratings
Majority rating from 3 analysts.
RPHM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.4M
-64.26%
Profit margin
0.00%
NaN%
RPHM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.57
-$0.71
-$0.25
-
Expected
-$0.52
-$0.57
-$0.58
-$0.44
-$0.10
Surprise
25.81%
-0.25%
22.88%
-42.75%
-
RPHM News
AllArticlesVideos
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
GlobeNewsWire·1 month ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
PRNewsWire·1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Reneo Pharmaceuticals stock?
Reneo Pharmaceuticals (RPHM) has a market cap of $50M as of July 27, 2024.
What is the P/E ratio for Reneo Pharmaceuticals stock?
The price to earnings (P/E) ratio for Reneo Pharmaceuticals (RPHM) stock is 0 as of July 27, 2024.
Does Reneo Pharmaceuticals stock pay dividends?
No, Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Reneo Pharmaceuticals dividend payment date?
Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders.
What is the beta indicator for Reneo Pharmaceuticals?
Reneo Pharmaceuticals (RPHM) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Reneo Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.